This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Chinweike Ukomadu: Innovator in Non-Alcoholic Steatohepatitis Treatment
Introduction
Chinweike Ukomadu is a notable inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of non-alcoholic steatohepatitis. His innovative work has the potential to impact many lives.
Latest Patents
Chinweike Ukomadu holds a patent for Licofligozin, which is aimed at the treatment, prevention, or delay of non-alcoholic steatohepatitis. This patent represents a crucial advancement in addressing this health condition. He has 1 patent to his name.
Career Highlights
Ukomadu is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on groundbreaking research and development projects. His expertise in the field has been instrumental in driving forward innovative solutions.
Collaborations
Chinweike Ukomadu has collaborated with esteemed colleagues, including Lloyd B Klickstein and C Daniel Meyers. These partnerships have fostered a collaborative environment that enhances the quality of research and innovation.
Conclusion
Chinweike Ukomadu is a prominent figure in the medical innovation landscape, particularly in the treatment of non-alcoholic steatohepatitis. His contributions through patents and collaborations highlight his commitment to advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile